Does decompressive surgery improve outcome in patients with metastatic epidural spinal-cord compression?

2006 ◽  
Vol 2 (1) ◽  
pp. 10-11 ◽  
Author(s):  
David E Gerber ◽  
Stuart A Grossman
Spine ◽  
2016 ◽  
Vol 41 (18) ◽  
pp. 1469-1476 ◽  
Author(s):  
Mingxing Lei ◽  
Jianjie Li ◽  
Yaosheng Liu ◽  
Weigang Jiang ◽  
Shubin Liu ◽  
...  

2021 ◽  
Vol 202 ◽  
pp. 106509
Author(s):  
Alexander Younsi ◽  
Lennart Riemann ◽  
Basem Ishak ◽  
Moritz Scherer ◽  
Andreas W. Unterberg ◽  
...  

2020 ◽  
Vol 11 ◽  
pp. 352
Author(s):  
Hela Ghedira ◽  
Khaled Radhouane ◽  
Essia Mezni ◽  
Safia Yahiaoui ◽  
Hela Stambouli ◽  
...  

Background: Various hematological malignancies, including multiple myeloma, plasmacytoma, aggressive lymphoma, and indolent lymphoma, rarely result in spinal cord compression. Methods: Here, we retrospectively analyzed 32 patients with multiple myeloma (50%), plasmacytoma (13%), aggressive lymphoma (28%), and indolent lymphoma (9%), resulting in spinal cord compression (2004 and 2016). Patients averaged 57 years of age and presented with the indolent onset of spinal cord compression (91% of cases) resulting mostly in motor deficits (69%). Results: Local treatment modalities included radiotherapy (RT) (28%) alone, decompressive surgery (28%) alone, or decompressive surgery with consolidation RT (40%). The 1-year overall survival was 70%, and the progression-free survival frequency was 62%. Conclusion: This study highlighted the importance of standardizing the indications for RT alone versus RT with surgery depending on the patient’s underlying pathological diagnosis, neurological deficits, and radiological findings.


2009 ◽  
Vol 11 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Kaisorn L. Chaichana ◽  
Courtney Pendleton ◽  
Daniel M. Sciubba ◽  
Jean-Paul Wolinsky ◽  
Ziya L. Gokaslan

Object Metastatic epidural spinal cord compression (MESCC) is a relatively common and debilitating complication of metastatic disease that often results in neurological deficits. Recent studies have supported decompressive surgery over radiation therapy for patients who present with MESCC. These studies, however, have grouped all patients with different histological types of metastatic disease into the same study population. The differential outcomes for patients with different histological types of metastatic disease therefore remain unknown. Methods An institutional database of patients undergoing decompressive surgery for MESCC at an academic tertiary-care institution between 1996 and 2006 was retrospectively reviewed. Patients with primary lung, breast, prostate, kidney, or gastrointestinal (GI) cancer or melanoma were identified. Fisher exact and log-rank analyses were used to compare pre-, peri-, and postoperative variables and survival for patients with these different types of primary cancers. Results Twenty-seven patients with primary lung cancer, 26 with breast cancer, 20 with prostate cancer, 21 with kidney cancer, 13 with GI cancer, and 7 with melanoma were identified and categorized. All of these patients were followed up for a mean ± SD of 10.8 ± 3.8 months following surgery. Patients with primary lung and prostate cancers were typically older than patients with other types of primary cancers. Patients with prostate cancer had the shortest duration of symptoms and more commonly presented with motor deficits, while patients with breast cancer more commonly had cervical spine involvement and compression fractures. For all histological types, > 90% of patients retained the ability to ambulate following surgery. However, the group with the highest percentage of patients who regained ambulatory function after decompressive surgery was the lung cancer group. Patients with breast or kidney cancer and those with melanoma had the highest median duration of survival following decompressive surgery. Conclusions The present study identifies differences in presenting symptoms, operative course, perioperative complications, long-term ambulatory outcomes, and duration of survival for patients with lung, breast, prostate, kidney, and GI cancers and melanoma. This understanding may allow better risk stratification for patients with MESCC.


Sign in / Sign up

Export Citation Format

Share Document